NCT03326752 - Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

September 19, 2019

Study Completion Date

September 19, 2019

Conditions

Advanced Non Small Cell Lung Cancer

Interventions

DRUG

DV281

\- Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.

DEVICE

Breath Actuated Nebulizer

Breath-actuated, electronic system designed to aerosolize liquid medication.

DRUG

DV281 (RP2D)

\- Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.

DRUG

Approved Anti-PD-1 Inhibitor

FDA approved Anti-PD-1 Inhibitor

Trial Locations (6)

Virginia Cancer Specialists, Fairfax

Sarah Cannon Research Institute, Nashville

Allina Health, Virginia Piper Cancer Institute, Minneapolis

Ronald Reagan University of California Los Angeles Medical Center, Santa Monica

Moores UC San Diego Cancer Center, La Jolla

Seattle Cancer Care Alliance, Seattle